PL2132229T3 - Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka - Google Patents

Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka

Info

Publication number
PL2132229T3
PL2132229T3 PL08706941.5T PL08706941T PL2132229T3 PL 2132229 T3 PL2132229 T3 PL 2132229T3 PL 08706941 T PL08706941 T PL 08706941T PL 2132229 T3 PL2132229 T3 PL 2132229T3
Authority
PL
Poland
Prior art keywords
growth factor
factor receptor
epidermal growth
receptor antibody
antibody compositions
Prior art date
Application number
PL08706941.5T
Other languages
English (en)
Inventor
Mikkel Wandahl Pedersen
Lucilla Steinaa
Allan Jensen
Klaus Koefoed
Per-Johan Meijer
Robert Carlsson
Charles Pyke
Lars Soegaard Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39495833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2132229(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2132229T3 publication Critical patent/PL2132229T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PL08706941.5T 2007-03-01 2008-02-27 Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka PL2132229T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700317 2007-03-01
US90477307P 2007-03-05 2007-03-05
DKPA200701016 2007-07-10
US92972707P 2007-07-11 2007-07-11

Publications (1)

Publication Number Publication Date
PL2132229T3 true PL2132229T3 (pl) 2016-12-30

Family

ID=39495833

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08706941.5T PL2132229T3 (pl) 2007-03-01 2008-02-27 Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka

Country Status (18)

Country Link
US (3) US7887805B2 (pl)
EP (2) EP2725036B1 (pl)
JP (1) JP5726417B2 (pl)
KR (2) KR101676622B1 (pl)
CN (2) CN101675075B (pl)
AU (1) AU2008221118B2 (pl)
BR (1) BRPI0808551B1 (pl)
CA (1) CA2676049C (pl)
DK (1) DK2132229T3 (pl)
ES (1) ES2582386T3 (pl)
HK (2) HK1134826A1 (pl)
IL (2) IL199725A (pl)
MX (2) MX2009008909A (pl)
NZ (2) NZ597466A (pl)
PL (1) PL2132229T3 (pl)
RU (1) RU2013119724A (pl)
TW (1) TWI426083B (pl)
WO (1) WO2008104183A2 (pl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101676622B1 (ko) 2007-03-01 2016-11-17 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
KR20090118993A (ko) * 2007-03-01 2009-11-18 심포젠 에이/에스 동족체 항체 클로닝 방법
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
WO2009030239A1 (en) 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
WO2009086411A2 (en) * 2007-12-27 2009-07-09 Abbott Laboratories Negative mimic antibody for use as a blocking reagent in bnp immunoassays
WO2010022738A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
WO2010022736A2 (en) 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
KR20110081284A (ko) * 2008-10-06 2011-07-13 심포젠 에이/에스 조합 약물 제품에 대한 약물 후보물질의 동정방법 및 선택방법
FR2942928B1 (fr) 2009-03-03 2011-04-01 Alcatel Lucent Procede et systeme de gestion multicriteres de notifications de presence
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
MX2012003538A (es) * 2009-10-09 2012-08-03 Symphogen As Cuantificacion multiple de proteinas recombinantes individuales en una mezcla mediante peptidos distintivos y espectrometria de masas.
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
US9096660B2 (en) 2010-04-26 2015-08-04 Abraxis Bioscience, Llc SPARC binding antibodies and uses thereof
WO2011140151A1 (en) * 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
CA2798273A1 (en) * 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
MX2013004761A (es) * 2010-10-29 2013-08-27 Immunogen Inc Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
BR112013010569A2 (pt) 2010-10-29 2017-07-04 Immunogen Inc moléculas de ligação de egfr não antagonísticas e imunoconjugados das mesma
EP2635604B1 (en) * 2010-11-01 2016-11-30 Symphogen A/S Pan-her antibody composition
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
CA2981662C (en) 2011-01-14 2019-02-05 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
CA2825255C (en) 2011-01-24 2021-05-18 Ym Biosciences Inc. Antibodies selective for cells presenting egfr at high density
DK2683736T3 (en) 2011-03-09 2018-04-23 Cell Signaling Technology Inc METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIES
SG192844A1 (en) 2011-03-11 2013-09-30 Merrimack Pharmaceuticals Inc Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
BR112013022887A2 (pt) 2011-03-15 2016-12-06 Merrimack Pharmaceuticals Inc superação de resistência a inibidores de via de erbb
US20120258502A1 (en) * 2011-04-08 2012-10-11 Vinod Pandiripally Method of producing recombinant plasmid dna using substantially solid growth medium
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
KR20140105765A (ko) 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
EP3663314A1 (en) * 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
KR101933990B1 (ko) 2012-05-02 2018-12-31 심포젠 에이/에스 인간화 ｐａｎ­ｈｅｒ 항체 조성물
WO2014038025A1 (ja) * 2012-09-05 2014-03-13 Ｓｃｉｖａｘ株式会社 細胞の上皮性維持に作用する物質のスクリーニング方法
US20150293105A1 (en) * 2012-10-26 2015-10-15 The University Of Queensland Methods for classifying tumors and uses therefor
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
US9856319B2 (en) * 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
CN104059148B (zh) * 2013-03-18 2016-09-07 回而生医药科技（北京）有限公司 人源化抗人表皮生长因子受体抗体及其应用
SG11201601770YA (en) * 2013-09-12 2016-04-28 Halozyme Inc Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015112749A2 (en) * 2014-01-22 2015-07-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
GB201402591D0 (en) * 2014-02-14 2014-04-02 Memo Therapeutics Ag Method for recovering two or more genes, or gene products, encoding an immunoreceptor
US20170176419A1 (en) * 2014-03-26 2017-06-22 Siemens Healthcare Diagnostics Inc. Luminescent oxygen channeling immunoassay utilizing three antibodies and methods of production and use thereof
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
MA40968A (fr) * 2014-10-31 2017-10-04 Formation Biologics Inc Polythérapie à base d'anticorps anti-egfr
ES2926384T3 (es) * 2015-02-06 2022-10-25 Nat Univ Singapore Métodos para mejorar la eficacia de células inmunitarias terapéuticas
KR20170138539A (ko) 2015-04-24 2017-12-15 메리맥 파마슈티컬즈, 인크. 표피 성장 인자 수용체(egfr)의 세포외 도메인 내에 돌연변이를 갖는 환자를 3종의 완전 인간 단클론성 항-egfr 항체의 조합물로 치료하는 방법
EP3429623A1 (en) 2016-03-15 2019-01-23 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
WO2017205014A1 (en) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
JP7011764B2 (ja) 2016-07-07 2022-01-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗体アジュバント複合体
US10550183B2 (en) 2016-11-22 2020-02-04 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
JP7360324B2 (ja) * 2016-12-23 2023-10-12 ビステラ， インコーポレイテッド 結合ポリペプチドおよびそれを作製する方法
CA3054381A1 (en) * 2017-02-22 2018-08-30 University Of Saskatchewan Egfr-binding agents and uses thereof
WO2018166119A1 (zh) * 2017-03-14 2018-09-20 北京伟峰益民科技有限公司 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用
EP3665270A4 (en) 2017-08-10 2021-04-21 National University of Singapore T-LYMPHOCYTES T-LYMPHOCYTE RECEPTOR-DEFICIENT CHEMERICAL ANTIGEN RECEPTOR AND METHODS OF USE
EP3695013A1 (en) 2017-08-30 2020-08-19 Symphogen A/S Compositions and methods for treating cancer with anti-egfr antibodies
WO2019114793A1 (zh) * 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
US11274035B2 (en) 2019-04-24 2022-03-15 X-Celeprint Limited Overhanging device structures and related methods of manufacture
US20210002128A1 (en) 2018-12-03 2021-01-07 X-Celeprint Limited Enclosed cavity structures
US10456776B1 (en) 2019-02-21 2019-10-29 King Saud University Method of fabricating a photocatalyst for water splitting
KR20220004634A (ko) 2019-03-15 2022-01-11 볼트 바이오테라퓨틱스 인코퍼레이티드 Her2를 표적으로 하는 면역접합체
CN111018990A (zh) * 2020-02-10 2020-04-17 张喜田 一种新型的重组抗表皮生长因子受体单克隆抗体及其应用
AR127234A1 (es) 2021-10-04 2024-01-03 Servier Lab Terapia del cáncer dirigida a nkg2a
AR127893A1 (es) 2021-12-10 2024-03-06 Servier Lab Terapia del cáncer dirigida a egfr

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
HU219537B (hu) 1991-03-06 2001-05-28 Merck Patent Gmbh. Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására
WO1994000136A1 (en) 1992-06-30 1994-01-06 Oncologix, Inc. A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
WO2001070985A2 (en) 2000-03-23 2001-09-27 Greenville Hospital System Bi-functional cancer treatment agents
DE60116753T2 (de) * 2000-05-19 2006-09-14 Scancell Ltd. Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
US6849259B2 (en) * 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
HUP0303173A2 (hu) * 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
EP1417232B1 (en) * 2001-06-13 2014-12-03 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2003012072A2 (en) * 2001-08-03 2003-02-13 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
WO2003074705A1 (fr) 2002-03-01 2003-09-12 Japan Envirochemicals, Ltd. Proteines capables de se fixer sur des hormones environnementales et procede permettant de les produire
US20060002934A1 (en) 2002-05-15 2006-01-05 Birgit Luber Egf receptor antagonists in the treatment of gastric cancer
JP2006508899A (ja) 2002-05-20 2006-03-16 アブジエニツクス・インコーポレイテツド ＥＧＦｒに対する抗体を使用する腎癌の治療方法
EP2263691B1 (en) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
CA2501818C (en) * 2002-10-10 2012-03-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Pharmaceutical compositions directed to erb-b1 receptors
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
WO2004061104A2 (en) 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
JP4579836B2 (ja) 2004-01-23 2010-11-10 株式会社グリーンペプタイド 上皮細胞増殖因子受容体（ｅｇｆｒ）由来ペプチド
US20110142822A1 (en) 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
AU2005263334C1 (en) * 2004-07-20 2011-01-20 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
EA014182B1 (ru) 2004-07-20 2010-10-29 Симфоген А/С КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ
KR20200058588A (ko) 2005-01-21 2020-05-27 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
ZA200707078B (en) 2005-02-23 2008-11-26 Genentech Inc Extending time to disease progression or survival in cancer patients
JP2008535477A (ja) 2005-02-24 2008-09-04 アムジエン・インコーポレーテツド 上皮成長因子受容体変異
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2006110478A2 (en) 2005-04-11 2006-10-19 Novartis Ag Mutations and polymorphisms of epidermal growth factor receptor
WO2006108627A1 (en) 2005-04-14 2006-10-19 Merck Patent Gmbh Anti-egfr antibody therapy based on an increased copy number of the egfr gene in tumor tissues
EP1877083A2 (en) 2005-04-27 2008-01-16 Welson Pharmaceuticals, Inc. Antibodies for the treatment of cancers
RS54271B1 (en) * 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
JP2009500458A (ja) * 2005-07-11 2009-01-08 マクロジェニクス，インコーポレーテッド ヒト化抗ｃｄ１６ａ抗体を用いる自己免疫疾患の治療方法
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
MX2008011280A (es) 2006-03-06 2008-09-12 Symphogen As Anticuerpor policlonal recombinante para el tratamiento de infecciones por el virus sincitial respiratorio.
KR20090118993A (ko) * 2007-03-01 2009-11-18 심포젠 에이/에스 동족체 항체 클로닝 방법
KR101676622B1 (ko) * 2007-03-01 2016-11-17 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
WO2010022736A2 (en) * 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
US9155802B2 (en) * 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition

Also Published As

Publication number Publication date
US20110129855A1 (en) 2011-06-02
KR101676622B1 (ko) 2016-11-17
IL216850A0 (en) 2012-01-31
BRPI0808551B1 (pt) 2022-04-05
EP2132229B1 (en) 2016-05-11
MX338151B (es) 2016-04-05
NZ597466A (en) 2013-08-30
JP5726417B2 (ja) 2015-06-03
AU2008221118A1 (en) 2008-09-04
US7887805B2 (en) 2011-02-15
KR101805140B1 (ko) 2017-12-05
ES2582386T3 (es) 2016-09-12
CN104151430A (zh) 2014-11-19
BRPI0808551A2 (pt) 2014-08-19
MX2009008909A (es) 2009-08-28
US20110135636A1 (en) 2011-06-09
EP2132229A2 (en) 2009-12-16
IL199725A0 (en) 2010-04-15
JP2010535012A (ja) 2010-11-18
CN101675075B (zh) 2014-06-18
EP2725036A1 (en) 2014-04-30
IL216850A (en) 2014-06-30
US8414896B2 (en) 2013-04-09
WO2008104183A3 (en) 2008-11-13
TWI426083B (zh) 2014-02-11
DK2132229T3 (en) 2016-06-20
US20090004192A1 (en) 2009-01-01
AU2008221118B2 (en) 2013-10-03
CA2676049A1 (en) 2008-09-04
KR20100014722A (ko) 2010-02-10
CA2676049C (en) 2018-04-10
KR20160132132A (ko) 2016-11-16
TW200902552A (en) 2009-01-16
WO2008104183A2 (en) 2008-09-04
HK1197252A1 (en) 2015-01-09
NZ578943A (en) 2012-09-28
IL199725A (en) 2015-06-30
CN101675075A (zh) 2010-03-17
HK1134826A1 (zh) 2010-06-11
RU2013119724A (ru) 2014-11-10
EP2725036B1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
HK1197252A1 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
ZA201100301B (en) Recombinant anti-epidermal growth factor receptor antibody compositions
HK1249053A1 (zh) 成纖維細胞生長因子受體2的單克隆抗體
HRP20182146T1 (hr) Formulacije protutijela natalizumab
IL229512A0 (en) Anti-vegf antibodies
HK1138790A1 (en) Anti-sclerostin antibodies
PL2195026T3 (pl) Przeciwciała przeciw sklerostynie
IL204536A0 (en) Anti - il -6 receptor antibody
HK1207652A1 (en) Antibody formulations
EP2173163A4 (en) ANTIBODY FORMULATIONS
IL236236A (en) Antibodies to the fam26f polypeptide
ZA200905341B (en) Recombinant anti-epidermal growth factor receptor antibody compositions
EP2167635A4 (en) ANTIBODY FORMULATIONS